Skip to main content
ERAS
NASDAQ Life Sciences

Erasca and Tango Therapeutics Launch Clinical Collaboration for Combination Cancer Therapy

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$15.15
Mkt Cap
$4.681B
52W Low
$1.01
52W High
$15.27
52W Position info
1400% above low
Off High info
at 52W high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ERAS has more than doubled off its 52-week low of $1.01.

Summary

Erasca and Tango Therapeutics have announced a clinical collaboration and supply agreement to evaluate Erasca's pan-RAS molecular glue, ERAS-0015, in combination with Tango's PRMT5 inhibitor, vopimetostat (TNG462). This partnership will support a Phase 1/2 clinical trial targeting patients with MTAP-deleted pancreatic or MTAP-deleted RAS-mutant non-small cell lung cancer, addressing a significant unmet medical need. Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the clinical trial. This collaboration is a material pipeline development for Erasca, expanding the potential clinical utility and market for its key asset, ERAS-0015, through a novel combination approach. Investors will closely watch for initial data from this Phase 1/2 trial, as positive results could significantly de-risk both compounds and validate the dual-targeted strategy.

At the time of this announcement, ERAS was trading at $15.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $1.01 to $15.27. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ERAS - Latest Insights

ERAS
Nov 20, 2026, 10:40 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $14.01
Real-time Price: $13.74 info
Change: -$0.270 (-2%) info
Market Cap: $4.777B info
ERAS
Nov 20, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.75
Real-time Price: $13.74 info
Change: -$0.0100 (-0.07%) info
Market Cap: $4.777B info
ERAS
Nov 20, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.99
Real-time Price: $13.74 info
Change: -$0.250 (-2%) info
Market Cap: $4.777B info
ERAS
Nov 17, 2026, 6:40 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.99
Real-time Price: $13.74 info
Change: -$0.250 (-2%) info
Market Cap: $4.777B info
ERAS
Nov 12, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.74 info
Change: -$2.04 (-13%) info
Market Cap: $4.777B info